Ads
related to: combination drugs for hiv patients- DESCOVY® Co-Pay Card
Help Patients Pay For DESCOVY®
View Patient Eligibility
- DESCOVY® Guidelines
Learn About National Guideline
Recommendations for DESCOVY®.
- Financial Assistance
Help Eligible Patients Save On
DESCOVY® - Eligibility Required.
- DESCOVY® FAQs
Read More About DESCOVY®
Frequently Asked Questions
- See $0 Co-Pay Eligibility
Financial Assistance For DESCOVY®
Help Eligible Patients Save
- DESCOVY® Candidates
Learn If DESCOVY® Might Be
Appropriate For Your Patients
- DESCOVY® Co-Pay Card
Search results
Results From The WOW.Com Content Network
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
Schematic description of the mechanism of the four classes of available antiretroviral drugs against HIV. There are six classes of drugs, which are usually used in combination, to treat HIV infection. Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life-cycle that the drug inhibits. Typical combinations include ...
Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [2] It contains two antiretroviral medications, lamivudine and zidovudine. [2] It is used together with other antiretrovirals. [2] It is taken by mouth twice a day. [2] [3]
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) of HIV-1. Tenofovir is a nucleotide reverse transcriptase inhibitor of HIV-1, and it can be classified as an NtRTI. These three drugs work in combination to target the HIV reverse transcriptase protein in three ways, which reduces the virus's capacity to mutate. [5]
Raltegravir (Isentress), developed by Merck & Co., was the first INSTI approved by the FDA in October 2007.; Elvitegravir (Vitekta), licensed by Gilead Sciences from Japan Tobacco, was approved by the U.S. Food and Drug Administration in August 2012, for use in adults starting HIV treatment for the first time as part of the fixed dose combination with emtricitabine and tenofovir disoproxil ...
Combination therapy for HIV, often called highly active antiretroviral therapy (HAART), is composed of two or more types of antiretroviral drugs. Combination therapy decreases the likelihood that drug resistance will occur, because it is unlikely that the HIV-1 strains will be able to mutate enough to become resistant to all drugs being used in ...
Ads
related to: combination drugs for hiv patients